This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Onishi, J.
Right arrow Articles by Kurtz, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Onishi, J.
Right arrow Articles by Kurtz, M. B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2000, p. 368-377, Vol. 44, No. 2
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Discovery of Novel Antifungal (1,3)-beta -D-Glucan Synthase Inhibitors

J. Onishi,1,* M. Meinz,1 J. Thompson,1 J. Curotto,1 S. Dreikorn,1 M. Rosenbach,1 C. Douglas,1 G. Abruzzo,1 A. Flattery,1 L. Kong,1 A. Cabello,2 F. Vicente,2 F. Pelaez,2 M. T. Diez,2 I. Martin,2 G. Bills,3 R. Giacobbe,3 A. Dombrowski,3 R. Schwartz,3 S. Morris,3 G. Harris,3 A. Tsipouras,3 K. Wilson,3 and M. B. Kurtz1

Departments of Infectious Diseases1 and Natural Products Drug Discovery,3 Merck Research Laboratories, Rahway, NJ 07065-0900,3 and Centro de Investigación Básica-Natural Products Drug Discovery,2 MSD-Spain, Madrid 28027, Spain2

Received 7 September 1999/Returned for modification 25 October 1999/Accepted 10 November 1999

The increasing incidence of life-threatening fungal infections has driven the search for new, broad-spectrum fungicidal agents that can be used for treatment and prophylaxis in immunocompromised patients. Natural-product inhibitors of cell wall (1,3)-beta -D-glucan synthase such as lipopeptide pneumocandins and echinocandins as well as the glycolipid papulacandins have been evaluated as potential therapeutics for the last two decades. As a result, MK-0991 (caspofungin acetate; Cancidas), a semisynthetic analogue of pneumocandin Bo, is being developed as a broad-spectrum parenteral agent for the treatment of aspergillosis and candidiasis. This and other lipopeptide antifungal agents have limited oral bioavailability. Thus, we have sought new chemical structures with the mode of action of lipopeptide antifungal agents but with the potential for oral absorption. Results of natural-product screening by a series of newly developed methods has led to the identification of four acidic terpenoid (1,3)-beta -D-glucan synthase inhibitors. Of the four compounds, the in vitro antifungal activity of one, enfumafungin, is comparable to that of L-733560, a close analogue of MK-0991. Like the lipopeptides, enfumafungin specifically inhibits glucan synthesis in whole cells and in (1,3)-beta -D-glucan synthase assays, alters the morphologies of yeasts and molds, and produces a unique response in Saccharomyces cerevisiae strains with point mutations in FKS1, the gene which encodes the large subunit of glucan synthase.

* Corresponding author. Mailing address: Department of Infectious Diseases, Merck Research Laboratories, R80Y-225 Infectious Diseases, P.O. Box 2000, Rahway, NJ 07065-0900. Phone: (732) 594-5515. Fax: (732) 594-1399. E-mail: jan_onishi{at}merck.com.

Antimicrobial Agents and Chemotherapy, February 2000, p. 368-377, Vol. 44, No. 2
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Sharifmoghadam, M. R., Valdivieso, M.-H. (2009). The Fission Yeast SEL1 Domain Protein Cfh3p: A NOVEL REGULATOR OF THE GLUCAN SYNTHASE Bgs1p WHOSE FUNCTION IS MORE RELEVANT UNDER STRESS CONDITIONS. J. Biol. Chem. 284: 11070-11079 [Abstract] [Full Text]  
  • Kitamura, A., Someya, K., Hata, M., Nakajima, R., Takemura, M. (2009). Discovery of a Small-Molecule Inhibitor of {beta}-1,6-Glucan Synthesis. Antimicrob. Agents Chemother. 53: 670-677 [Abstract] [Full Text]  
  • Garcia-Effron, G., Park, S., Perlin, D. S. (2009). Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints. Antimicrob. Agents Chemother. 53: 112-122 [Abstract] [Full Text]  
  • Bennett, J. E. (2006). Echinocandins for Candidemia in Adults without Neutropenia. NEJM 355: 1154-1159 [Full Text]  
  • Selvakumar, D., Miyamoto, M., Furuichi, Y., Komiyama, T. (2006). Inhibition of Fungal {beta}-1,3-Glucan Synthase and Cell Growth by HM-1 Killer Toxin Single-Chain Anti-Idiotypic Antibodies.. Antimicrob. Agents Chemother. 50: 3090-3097 [Abstract] [Full Text]  
  • Tanida, T., Okamoto, T., Ueta, E., Yamamoto, T., Osaki, T. (2006). Antimicrobial peptides enhance the candidacidal activity of antifungal drugs by promoting the efflux of ATP from Candida cells. J Antimicrob Chemother 57: 94-103 [Abstract] [Full Text]  
  • Moudgal, V., Little, T., Boikov, D., Vazquez, J. A. (2005). Multiechinocandin- and Multiazole-Resistant Candida parapsilosis Isolates Serially Obtained during Therapy for Prosthetic Valve Endocarditis. Antimicrob. Agents Chemother. 49: 767-769 [Abstract] [Full Text]  
  • Dowell, J. A., Stogniew, M., Krause, D., Henkel, T., Weston, I. E. (2005). Assessment of the Safety and Pharmacokinetics of Anidulafungin When Administered With Cyclosporine. J Clin Pharmacol 45: 227-233 [Abstract] [Full Text]  
  • Sussman, A., Huss, K., Chio, L.-C., Heidler, S., Shaw, M., Ma, D., Zhu, G., Campbell, R. M., Park, T.-S., Kulanthaivel, P., Scott, J. E., Carpenter, J. W., Strege, M. A., Belvo, M. D., Swartling, J. R., Fischl, A., Yeh, W.-K., Shih, C., Ye, X. S. (2004). Discovery of Cercosporamide, a Known Antifungal Natural Product, as a Selective Pkc1 Kinase Inhibitor through High-Throughput Screening. Eukaryot Cell 3: 932-943 [Abstract] [Full Text]  
  • Arikan, S., Paetznick, V., Rex, J. H. (2002). Comparative Evaluation of Disk Diffusion with Microdilution Assay in Susceptibility Testing of Caspofungin against Aspergillus and Fusarium Isolates. Antimicrob. Agents Chemother. 46: 3084-3087 [Abstract] [Full Text]  
  • Ripeau, J.-S., Aumont, F., Belhumeur, P., Ostrosky-Zeichner, L., Rex, J. H., de Repentigny, L. (2002). Effect of the Echinocandin Caspofungin on Expression of Candida albicans Secretory Aspartyl Proteinases and Phospholipase In Vitro. Antimicrob. Agents Chemother. 46: 3096-3100 [Abstract] [Full Text]  
  • Firon, A., Beauvais, A., Latge, J.-P., Couve, E., Grosjean-Cournoyer, M.-C., d'Enfert, C. (2002). Characterization of Essential Genes by Parasexual Genetics in the Human Fungal Pathogen Aspergillus fumigatus: Impact of Genomic Rearrangements Associated With Electroporation of DNA. Genetics 161: 1077-1087 [Abstract] [Full Text]  
  • Petraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Schaufele, R. L., Francesconi, A., Bacher, J., Avila, N. A., Walsh, T. J. (2002). Antifungal Efficacy of Caspofungin (MK-0991) in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits: Pharmacokinetics, Drug Disposition, and Relationship to Galactomannan Antigenemia. Antimicrob. Agents Chemother. 46: 12-23 [Abstract] [Full Text]  
  • Reichenberger, F., Habicht, J.M., Gratwohl, A., Tamm, M. (2001). Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J 19: 743-755 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»